ASX RELEASE 1 November 2023

Paradigm to Recommence Trading

Paradigm Biopharmaceuticals Ltd (ASX:PAR) ("Paradigm" or "the Company") wishes to advise that in accordance with the Entitlement Offer timetable, trading in Paradigm shares will resume from the commencement of trading today.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm's current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of iPPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).

Authorised for release by the Company Secretary on behalf of the Board.

To learn more please visit: https://paradigmbiopharma.com/

FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com